Vifor Pharma (GNHAF) Short Interest Ratio & Short Volume $181.25 0.00 (0.00%) As of 10/21/2022 Add Compare Share Share Short Interest Stock AnalysisBuy This Stock Vifor Pharma Short Interest DataVifor Pharma (GNHAF) has a short interest of 300 shares. This marks a 0.00% change in short interest from the previous month. The short interest ratio (days to cover) is 0.0, indicating that it would take 0.0 days of the average trading volume of 100 shares to cover all short positions.Current Short Interest300 sharesPrevious Short Interest300 sharesChange Vs. Previous MonthNo ChangeDollar Volume Sold Short$54.38 thousandShort Interest Ratio0.0 Days to CoverLast Record DateOctober 15, 2022Today's Trading Volume0 sharesAverage Trading Volume100 sharesToday's Volume Vs. Average0% Short Selling Vifor Pharma? Sign up to receive the latest short interest report for Vifor Pharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartGNHAF Short Interest Over TimeGNHAF Days to Cover Over TimeGNHAF Percentage of Float Shorted Over Time Vifor Pharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/15/2022300 shares $54.38 thousand No ChangeN/A0 $181.25 9/30/2022300 shares $54.38 thousand No ChangeN/A0 $181.25 9/15/2022300 shares $54.38 thousand No ChangeN/A1.5 $181.25 8/31/2022300 shares $54.38 thousand -25.0%N/A0 $181.25 8/15/2022400 shares $69.70 thousand -42.9%N/A4 $174.25 7/31/2022700 shares $128.45 thousand -12.5%N/A0 $183.50 7/15/2022800 shares $146.80 thousand No ChangeN/A0 $183.50 6/30/2022800 shares $138.60 thousand +14.3%N/A8 $173.25 6/15/2022700 shares $121.28 thousand -75.9%N/A3.5 $173.25 5/31/20222,900 shares $502.43 thousand -75.2%N/A0 $173.25 Get the Latest News and Ratings for GNHAF and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Vifor Pharma and its competitors with MarketBeat's FREE daily newsletter. 5/15/202211,700 shares $2.03 million +1,571.4%N/A0 $173.25 4/30/2022700 shares $121.28 thousand -22.2%N/A0 $173.25 4/15/2022900 shares $155.93 thousand -86.6%N/A0 $173.25 3/31/20226,700 shares $1.16 million -61.5%N/A67 $173.51 3/15/202217,400 shares $2.98 million -56.1%N/A58 $171.00 2/28/202239,600 shares $6.69 million +20.0%N/A396 $169.00 2/15/202233,000 shares $5.62 million +19.1%N/A330 $170.25 1/31/202227,700 shares $4.73 million -8.9%N/A277 $170.75 1/15/202230,400 shares $5.19 million -42.9%N/A304 $170.75 12/31/202153,200 shares $7.69 million -73.4%N/A532 $144.50 12/15/2021200,000 shares $28.90 million -72.5%N/A2000 $144.50 11/30/2021728,500 shares $92.52 million -1.3%N/A7285 $127.00 11/15/2021738,200 shares $91.91 million -1.7%N/A7382 $124.50 10/29/2021750,600 shares $96.64 million +2.8%N/A7506 $128.75 10/15/2021730,500 shares $99.71 million +9.8%N/A7305 $136.50 9/30/2021665,100 shares $85.25 million -2.1%N/A3325.5 $128.17 9/15/2021679,500 shares $97.30 million -2.3%N/A0 $143.20 8/31/2021695,600 shares $99.61 million -0.2%N/A3478 $143.20 8/13/2021696,800 shares $92.21 million -14.5%N/A0 $132.33 7/30/2021814,600 shares $107.80 million -8.5%N/A8146 $132.33 7/15/2021889,800 shares $117.75 million -4.3%N/A8898 $132.33 6/30/2021929,400 shares $134.01 million -3.4%N/A0 $144.19 6/15/2021962,400 shares $138.76 million -5.0%N/A9624 $144.19 5/28/20211,013,000 shares $146.06 million +10.0%N/A0 $144.19 5/14/2021920,800 shares $130.23 million +19.7%N/A0 $141.43 4/30/2021769,300 shares $108.80 million -4.8%N/A0 $141.43 4/15/2021808,200 shares $114.30 million -2.0%N/A8082 $141.43 3/31/2021824,400 shares $110.80 million +3.8%N/A0 $134.40 3/15/2021794,100 shares $106.73 million +8.1%N/A7941 $134.40 2/26/2021734,900 shares $95.54 million +16.9%N/A0 $130.00Elon’s BIGGEST warning yet? (Ad)Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough. Click here to see why Tesla's about to prove everyone wrong... again. 2/12/2021628,800 shares $81.74 million -5.5%N/A2096 $130.00 1/29/2021665,300 shares $98.80 million +28.0%N/A0 $148.50 1/15/2021422,300 shares $62.71 million -14.8%N/A4223 $148.50 12/31/2020456,400 shares $68.46 million +8.1%N/A0 $149.99 12/15/2020422,300 shares $63.34 million -14.8%N/A4223 $149.99 11/30/2020495,900 shares $62.18 million +3.9%N/A4959 $125.38 11/15/2020477,400 shares $59.86 million +15.0%N/A4774 $125.38 10/30/2020415,100 shares $54.46 million -0.8%N/A4151 $131.21 10/15/2020418,400 shares $55.45 million -0.8%N/A4184 $132.53 9/30/2020421,700 shares $61.47 million -0.1%N/A0 $145.77 9/15/2020422,000 shares $61.51 million +22.0%N/A4220 $145.77 8/31/2020345,900 shares $51.54 million +9.1%N/A0 $149.00 8/14/2020317,100 shares $44.37 million +2.9%N/A3171 $139.92 7/31/2020308,200 shares $44.38 million +9.9%N/A3082 $144.00 7/15/2020280,500 shares $41.79 million +21.1%N/A2805 $149.00 GNHAF Short Interest - Frequently Asked Questions What is Vifor Pharma's current short interest? Short interest is the volume of Vifor Pharma shares that have been sold short but have not yet been closed out or covered. As of October 15th, traders have sold 300 shares of GNHAF short. Learn More on Vifor Pharma's current short interest. Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Occidental Petroleum Corporation ($3.48 billion), Charter Communications, Inc. ($2.85 billion), Twitter, Inc. ($1.89 billion), T. Rowe Price Group, Inc. ($1.78 billion), Coinbase Global, Inc. ($1.77 billion), Pacific Gas & Electric Co. ($1.75 billion), Lucid Group, Inc. ($1.58 billion), Rivian Automotive, Inc. ($1.42 billion), Roblox Corporation ($1.39 billion), and Williams-Sonoma, Inc. ($1.33 billion). View all of the most shorted stocks. What does it mean to sell short Vifor Pharma stock? Short selling GNHAF is an investing strategy that aims to generate trading profit from Vifor Pharma as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Vifor Pharma? A short squeeze for Vifor Pharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of GNHAF, which in turn drives the price of the stock up even further. How often is Vifor Pharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including GNHAF, twice per month. The most recent reporting period available is October, 15 2022. More Short Interest Resources from MarketBeat Related Companies 1933 Industries Short Interest 4Cable TV International Short Interest 4Front Ventures Short Interest AB Science Short Interest Aleafia Health Short Interest Almirall Short Interest Alvotech Short Interest American Green Short Interest Avant Brands Short Interest Avicanna Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (OTCMKTS:GNHAF) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredNobel Prize Material Finally Goes CommercialA Nobel Prize–winning material just got its biggest breakthrough in 30 years. A little-known company has cr...True Market Insiders | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vifor Pharma AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Vifor Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
